Gjalt W. Huisman, PhD

Gjalt Huisman, PhD, is a seasoned expert in enzyme engineering with over 20 years of experience, including a decade dedicated to developing therapeutic enzymes. He is currently co-founder of Revel Pharmaceuticals, which is pioneering the use of engineered enzymes to target post-translational protein modifications for disease treatment. Dr. Huisman previously led efforts at Codexis, where his team advanced multiple therapeutic enzyme candidates—several with FDA Orphan Drug Designation—for conditions like phenylketonuria, Fabry disease, and maple syrup urine disease. Earlier in his career, he played a key role in enzyme process development for major drugs including Lipitor®, Xalkori® and Paxlovid®. Since 2022, he has served as a consultant to early-stage biotech firms and founded Embold Therapeutics, focused on developing disease-modifying treatments for Parkinson’s disease.